Another MCT1 inhibitor, AZD3965, has demonstrated antitumor activity in xenograft models by suppressing tumor growth, enhancing immune cell infiltration and cytotoxicity, and increasing tumor radiosensitivity [178, 179]. The gene discussed is SLC16A1; the disease is neoplasm.